India’s Dr. Reddy’s Laboratories posted a 2% rise in consolidated Q1 FY26 net profit and 11.4% growth in revenue, pushing shares up 3% despite cautious investor sentiment. With gRevlimid revenues set to fade, the company’s focus now shifts to the upcoming global launch of Semaglutide, a generic GLP-1 agonist, targeting key obesity and diabetes markets.
Shares of Dr Reddy’s Laboratories gained over 3% to ₹1,288 on July 24 following the release of its Q1 FY26 earnings, which reflected steady top-line growth and cautious optimism around its pipeline. Despite a mere 2% year-on-year increase in consolidated net profit to ₹1,418 crore, revenue for the quarter rose 11.4% to ₹8,545 crore, signaling robust sales performance across geographies.
The company’s EBITDA rose 5% to ₹2,278 crore, though margins moderated to 26.7% from 28.2% YoY, indicating pressure from higher input and operating costs.
Margin Compression and Revenue Mix Shift
While EBITDA growth was modest, the decline in margin points to increased R&D investments and sustained SG&A expenses as the company prepares for future launches. Gross margins saw contraction due to generic price erosion in the US and a higher contribution from lower-margin products.
Management acknowledged that Q2 FY26 would mark the last significant contribution from Lenalidomide (gRevlimid), a product that previously underpinned the company’s profitability. This aligns with market expectations that increased competition would rapidly erode revenues from this molecule in H2 FY26.
Semaglutide Strategy in Focus
Market attention is now turning toward the company’s plans for Semaglutide, a GLP-1 agonist being developed as a generic alternative to Ozempic/Wegovy. Dr Reddy’s aims to launch the product in Canada by January 2026, following the expiry of exclusivity. Additional rollouts are planned in over 80 markets by FY27.
Although the company has secured pen manufacturing capacity of 10–12 million units through partnerships, its proprietary manufacturing at the Vizag facility is only expected to commence in FY28. This delay could cap early revenues and limit immediate market share gains in the high-growth diabetes and weight management segments.
Also Read: A Billion-Dollar Signal: India’s Top Firms Shower Dividends in July
Equity View: Volatility Amid Transition
Dr Reddy’s stock remains down 10% year-to-date, reflecting broader investor caution amid product lifecycle transitions. While the Q1 revenue beat demonstrates operational resilience, the underlying pressure on margins and dependence on future product launches creates a mixed outlook.
Investors may weigh the short-term revenue contraction from gRevlimid against the medium-term opportunity in semaglutide and biologics. Execution on product launches and supply chain readiness will be crucial in determining whether the stock can reclaim upward momentum in the second half of FY26.
READ MORE ON